Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Adalimumab Effective in Treating Psoriasis, Regardless of Patient Characteristics: Presented at EADV By Jenny Powers PARIS -- September 20, 2008 -- Adalimumab is well tolerated and effective in the treatment of moderate to severe psoriasis, regardless of the patient's age, duration of illness, and recent treatment history, according to results presented here at the European Academy of Dermatology and Venereology (EADV). The year-long Randomized Controlled Evaluation of Adalimumab Every Other Week in Moderate to Severe Psoriasis Trial (REVEAL) was a double-blind, placebo-controlled evaluation of 1,212 patients at 81 centres in Canada and the United States. Lead author Alan Menter, MD, Baylor University Medical Center, Dallas, Texas, discussed the study findings in a poster presentation on September 18. Patients in REVEAL were randomised 1:1 to receive either placebo or adalimumab 80 mg at week 0, followed by 40 mg every other week from weeks 1 through 15. Patients had moderate to severe psoriasis, were naive to treatment with antitumour necrosis factor (TNF), and had failed topical therapy. A primary analysis was performed at week 16 using the Psoriasis Area and Severity Index (PASI), which describes a decrease of 50% or greater (PASI 50), 75% or greater (PASI 75), and 90% or greater (PASI 90) to evaluate patients' change from baseline in psoriasis involvement. More than 70% of patients treated with adalimumab achieved PASI 75 versus 6.5% of the placebo patients (P < .001), the investigators noted. Adalimumab response was similar across age groups, with 74%, 70%, and 61% of patients achieving PASI 75% in the 40-year-old, 40- to 64-year-old and >65-year-old groups, respectively. The duration of psoriasis did not alter the response to adalimumab, which remained consistent across disease-duration quartiles that ranged from <10 years to more than 65 years. Also, 78% and 68% of patients with a recent history of systemic biological and nonbiological treatment achieved PASI 75%, respectively. Treatment with adalimumab was well tolerated, with 96.2% of adalimumab-treated patients completing the initial phase versus 89.2% of the placebo group. Funding for this study was provided by Abbott Laboratories. [Presentation title: Adalimumab response is consistency across subgroups of patients with moderate to severe psoriasis: Results of REVEAL. Abstract FP1374] E-mail this page to a friend or colleague! To print, use this version